Last updated: March 9, 2026
What is NDC 49884-0786?
NDC 49884-0786 refers to Otezla (apremilast), a prescription medication approved for the treatment of psoriasis, psoriatic arthritis, and certain other inflammatory conditions. Marketed predominantly by Celgene (now part of BMS), Otezla has established itself within the immunomodulatory therapeutics space since its approval by the FDA in 2014.
Market Size and Demographics
Estimated Market Value (2023-2025)
- Global psoriasis market valued at approximately USD 4.5 billion in 2022.
- Estimated CAGR of 8%, projecting a market size of USD 7 billion by 2025.
- Psoriasis prevalence: affects approximately 2-4% of the global population, with higher incidences in North America and Europe.
- Treatment penetration: estimated at 60-70% in developed markets, with increasing adoption due to new formulations and expanded indications.
Key Competitors
- Biologics: Stelara (ustekinumab), Humira (adalimumab), Cosentyx (secukinumab), Tremfya (guselkumab).
- Oral options: Otezla, Xeljanz (tofacitinib).
Market Share
- Otezla's share (2022): approximately 12-15% of the global psoriasis treatment market, with preference in non-biologic segment due to oral administration.
- Growth Drivers:
- Non-injectable alternative appeals to patients with needle phobia.
- Expanded label for psoriatic arthritis (approved in 2019) widens its use case.
Price Analysis and Dynamics
Current Pricing (2023)
Reimbursement Landscape
- United States: Coverage by Medicaid, Medicare, and commercial insurers; patient copay assistance programs.
- Europe and Asia: Managed through national health systems, with variable reimbursement levels, impacting the net price.
Price Trends (2018-2023)
- Stable pricing in North America, with slight declines due to increased competition and biosimilar entries in biologic space.
- Pricing pressure arises from biosimilar developments and focus on cost-effectiveness.
Projected Market Trends and Price Outlook (2024-2027)
| Year |
Estimated Market Size (USD Billion) |
Expected Price per Prescription (USD) |
Key Factors Influencing Prices |
| 2024 |
5.2 |
1,800 – 2,200 |
Increased market competition, entry of generics in other indications, tighter reimbursement controls |
| 2025 |
6.0 |
1,750 – 2,150 |
Patent expiry approaching in major markets, price negotiations intensify |
| 2026 |
6.8 |
1,700 – 2,100 |
Biosimilar competition in biologics, further formulary restrictions |
| 2027 |
7.0 |
1,650 – 2,000 |
Market saturation, shift to value-based pricing models |
Patent and Regulatory Outlook
- Key patent expiry: Expected around 2025 in the U.S., opening pathways for generics or biosimilars.
- Regulatory developments: Expansion into new indications (e.g., Crohn's disease, rheumatoid arthritis) may sustain demand.
Strategic Implications
- Market share gain depends on continued differentiation, such as safety profile, patient adherence, and formulary access.
- Price erosion is likely with biosimilar and generic competition, especially post-patent expiration.
- Cost management will be crucial for maintaining profitability in mature markets.
Key Takeaways
- NDC 49884-0786 (Otezla) operates in a competitive landscape with stable but slowly declining prices due to patent expiry and biosimilar threats.
- The overall market size is set to grow steadily, driven by rising psoriasis prevalence and expanded indications.
- Price projections indicate a gradual decline in net prices over the next four years, influenced by competitive pressures and reimbursement dynamics.
- Future growth depends on innovation, expansion into new indications, and strategies to mitigate pricing erosion.
FAQs
Q1: What other indications are approved for apremilast?
A: Besides psoriasis and psoriatic arthritis, apremilast is being studied for Crohn’s disease, Behçet’s disease, and ankylosing spondylitis.
Q2: How does Otezla's price compare internationally?
A: Prices vary; USD 1,600-1,850 net in the U.S. vs significantly lower in Europe and Asia due to negotiated rebates and healthcare system differences.
Q3: What impacts patent expiry on pricing?
A: Patent expiration in key markets (around 2025 in the U.S.) allows biosimilars or generics to enter, typically causing price reductions.
Q4: How is market share expected to evolve?
A: While Otezla maintains a niche due to oral administration, biosimilar competition and new biologics are expected to erode its share over time.
Q5: What manufacturing or regulatory trends are influencing prices?
A: Patent cliff, biosimilar approvals, and health authority reimbursement policies are the primary factors affecting pricing.
References
- Marketline. (2022). Global psoriasis market report.
- IQVIA. (2022). US Prescription Market and Pricing Trends.
- European Medicines Agency. (2023). Summary of Product Characteristics – Otezla.
- FDA. (2014). Otezla (apremilast) approval.
- EvaluatePharma. (2022). Oncology and Immunology Market Data.
